Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk UTUC
NCT05837806Phase 2Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and disitamab vedotin in upper tract urothelial carcinoma (UTUC), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Pathological Complete Response at 3 months. Started Dec 2022; status: recruiting.
02
Drugs
tislelizumabdisitamab vedotin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT05837806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05837806.